| Model | Cell line | Species | PD‑L1 status | |-------|-----------|----------|--------------| | MC38 | Colon adenocarcinoma | C57BL/6 | High | | B16‑F10 | Melanoma | C57BL/6 | Moderate | | 4T1 | Triple‑negative breast carcinoma | BALB/c | Low‑moderate |
: A more whimsical interpretation suggests that ADN-388 might be part of a viral marketing campaign or an Easter egg hidden within software or a game. This theory proposes that the term is a clue or a riddle designed to engage and puzzle the audience, encouraging online searches and discussions. adn-388
[Your Name], Email: your.email@universityx.edu | Model | Cell line | Species |
[Your Name]¹, [Co‑author]², [Co‑author]³ Monoclonal antibodies (mAbs) targeting either PD‑1 (e
The PD‑1/PD‑L1 axis is a central immune checkpoint exploited by many cancers to suppress anti‑tumor T‑cell responses (1). Monoclonal antibodies (mAbs) targeting either PD‑1 (e.g., pembrolizumab) or PD‑L1 (e.g., atezolizumab) have transformed the therapeutic landscape, yet they suffer from limitations including intravenous administration, high production cost, and immune‑related adverse events (irAEs) (2). Small‑molecule inhibitors offer an attractive alternative: oral dosing, potential for blood‑brain barrier penetration, and the ability to fine‑tune pharmacokinetics (3). However, the large, flat protein‑protein interface of PD‑1/PD‑L1 has historically rendered it “undruggable” for low‑molecular‑weight ligands (4).